Lung cancer
A137 – A155
- A137: Differential expression and promoter methylation of globin family genes in lung cancer
- A138: Hypomethylation of LINE-1 and Alu-PV retrotransposble elements in lung cancer
- A139: Predictive power of the LLP risk model with SEZ6I SNP
- A140: Epigenetic deregulation of DIRAS3 in non-small cell lung cancer
- A141: TP73 promoter methylation in non-small cell lung carcinoma
- A142: The role of janus kinases (JAKs) and signal transducer and activators of transcription (STATs) in lung cancer biology
- A143: Defining the REST-regulome in neuroendocrine lung cancer
- A144: Peripheral blood SCG3 mRNA: a prognostic biomarker in small cell lung cancer
- A145: Determinants of the response to cisplatin in small cell lung cancer cell lines
- A146: qMSP assay development for early lung cancer detection
- A147: Quantitative sputum cytology to detect lung cancer
- A148: Real time RT-PCR methods used to identify microRNAs differentially expressed in a cell differentiation model and in non-small cell lung cancer
- A149: Preclinical development of vorinostat for small cell lung cancer (SCLC)
- A150: Peptide aptamer technology: a new way of diagnosing and treating cancer
- A151: Quality of life after radiotherapy and steroids in patients with inoperable brain metastases from non-small cell lung cancer: the QUARTZ trial
- A152: Adjuvant vinorelbine and cisplatin chemotherapy in resected non small cell lung cancer
- A153: A retrospective single institution review of toxicity rates with adjuvant platinum based combination chemotherapy in post-operative early stage lung cancer
- A154: Supportive care needs and mortality in lung cancer patients
- A155: Best supportive care in lung cancer trials – do we know what it is?
